These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30321314)

  • 1. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.
    Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D
    Clin Infect Dis; 2019 Jul; 69(2):207-214. PubMed ID: 30321314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.
    Avila-Ríos S; García-Morales C; Matías-Florentino M; Tapia-Trejo D; Hernández-Álvarez BF; Moreira-López SE; Quant-Durán CJ; Porras-Cortés G; Reyes-Terán G
    PLoS One; 2016; 11(10):e0164156. PubMed ID: 27736898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
    Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment.
    Hermans LE; Hofstra LM; Schuurman R; Ter Heine R; Burger DM; Talboom SAJ; De Jong D; Tempelman HA; Venter WDF; Nijhuis M; Wensing AMJ
    AIDS; 2022 Jun; 36(7):923-931. PubMed ID: 35113046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis.
    Bertagnolio S; Hermans L; Jordan MR; Avila-Rios S; Iwuji C; Derache A; Delaporte E; Wensing A; Aves T; Borhan ASM; Leenus A; Parkin N; Doherty M; Inzaule S; Mbuagbaw L
    J Infect Dis; 2021 Aug; 224(3):377-388. PubMed ID: 33202025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
    Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
    J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
    Lippman SA; Mooney AC; Puren A; Hunt G; Grignon JS; Prach LM; Gilmore HJ; Truong HM; Barnhart S; Liegler T
    BMC Infect Dis; 2020 Mar; 20(1):248. PubMed ID: 32216752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Drug Resistance Detected by Next-Generation Sequencing among ART-Naïve Individuals: A Systematic Review and Meta-Analysis.
    Ouyang F; Yuan D; Zhai W; Liu S; Zhou Y; Yang H
    Viruses; 2024 Feb; 16(2):. PubMed ID: 38400015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
    Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.